ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00818753
Recruitment Status : Completed
First Posted : January 8, 2009
Results First Posted : October 25, 2011
Last Update Posted : June 9, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).

Condition or disease Intervention/treatment Phase
Heart Catheterization Drug: dabigatran 110 mg Drug: dabigatran 150 mg Drug: unfractionated heparin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization
Study Start Date : January 2009
Actual Primary Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Dabigatran 110 mg
experimental drug therapy in this indication
Drug: dabigatran 110 mg
comparison of different dabigatran dosages with unfractionated heparin
Experimental: Dabigatran 150 mg
experimental drug therapy in this indication
Drug: dabigatran 150 mg
comparison of different dabigatran dosages with unfractionated heparin
Active Comparator: Unfractionated Heparin
standard therapy in this indication as comparator
Drug: unfractionated heparin
comparison of different dosages dabigatran with unfractionated heparin



Primary Outcome Measures :
  1. Percentage of Participants Who Require Anticoagulation and/or Have Clinical Signs of Catheter Related Thrombosis [ Time Frame: From 22 to 165 minutes ]
    Investigator reported outcome


Secondary Outcome Measures :
  1. Percentage of Participants Who Experienced Catheter Related Thrombi Requiring Rescue Anticoagulation Therapy [ Time Frame: From 22 to 165 minutes ]
    Investigator reported outcome

  2. Percentage of Participants Who Experienced Abrupt Vessel Closure, New Thrombus With Reduced Reflow or no Reflow [ Time Frame: From 22 to 165 minutes ]
    Investigator reported outcome

  3. Percentage of Participants Who Experienced Catheter Related Thrombi Not Resulting in Clinical Complications Including Guide-catheter (Wire) Thrombosis [ Time Frame: From 22 to 165 minutes ]
    Investigator reported outcome

  4. Number of Participants With Bleeding Events [ Time Frame: First administration until 7-14 days after PCI (Percutaneous Coronary Intervention) ]
    Bleeding is categorized using the TIMI criteria as major or minor bleeding. The time window for inclusion of bleeding events was up until 3 days post-procedure or discharge (whichever occurred first).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • patients between 18 and 85 years
  • due to undergo elective PCI
  • informed consent obtained

Exclusion criteria:

  • PCI lesion specific conditions
  • class III or IV congestive heart failure
  • severe hypertension
  • increased bleeding risk
  • thrombolytic therapy within 24 hours preceding randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00818753


Locations
Netherlands
1160.73.31004 Boehringer Ingelheim Investigational Site
Alkmaar, Netherlands
1160.73.31003 Boehringer Ingelheim Investigational Site
Nieuwegein, Netherlands
1160.73.1 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1160.73.31002 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00818753     History of Changes
Other Study ID Numbers: 1160.73
2007-007536-25 ( EudraCT Number: EudraCT )
First Posted: January 8, 2009    Key Record Dates
Results First Posted: October 25, 2011
Last Update Posted: June 9, 2014
Last Verified: December 2013

Additional relevant MeSH terms:
Calcium heparin
Heparin
Dabigatran
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors